Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Accured Expenses: 2016-2024

Historic Change in Accured Expenses for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $5.4 million.

  • Krystal Biotech's Change in Accured Expenses rose 204.69% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 893.15%. This contributed to the annual value of $5.4 million for FY2024, which is 18.28% up from last year.
  • Latest data reveals that Krystal Biotech reported Change in Accured Expenses of $5.4 million as of FY2024, which was up 18.28% from $4.6 million recorded in FY2023.
  • Krystal Biotech's Change in Accured Expenses' 5-year high stood at $5.4 million during FY2024, with a 5-year trough of $2.3 million in FY2020.
  • Over the past 3 years, Krystal Biotech's median Change in Accured Expenses value was $5.2 million (recorded in 2022), while the average stood at $5.0 million.
  • In the last 5 years, Krystal Biotech's Change in Accured Expenses surged by 321.39% in 2020 and then decreased by 11.89% in 2023.
  • Yearly analysis of 5 years shows Krystal Biotech's Change in Accured Expenses stood at $2.3 million in 2020, then rose by 17.35% to $2.7 million in 2021, then skyrocketed by 91.24% to $5.2 million in 2022, then dropped by 11.89% to $4.6 million in 2023, then increased by 18.28% to $5.4 million in 2024.